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Abstract: Type 2 diabetes has become a major burden to the health care systems worldwide. 
Among the drugs approved for this indication, glimepiride and rosiglitazone have gained sub-
stantial importance in routine use. While glimepiride stimulates β-cell secretion and leads to 
reduction of blood glucose values, rosiglitazone activates PPARγ and improves insulin resistance, 
at the vascular and metabolically active cells. Therefore, the combination of the two drugs may 
be an interesting approach to improve glycemic control and lower cardiovascular risk. A ﬁ  xed 
combination of both drugs has been approved for clinical use in the US and EU. The combination 
of glimepiride and rosiglitazone is generally well tolerated and the use of a ﬁ  xed combination 
may lead to improved adherence of the patients to their therapy. The purpose of this review is to 
evaluate the clinical data that have been published on this combination, appearing to represent 
a convenient way to obtain therapeutic targets in patients with type 2 diabetes mellitus.
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Introduction
Type 2 diabetes is a leading cause of morbidity and mortality in many countries and the 
number of cases is currently approaching pandemic proportions (Zimmet et al 2001). 
Patients with both types of diabetes mellitus have an increased risk of fatal cardiovascular 
events. About 75% patients with type 2 diabetes die from macrovascular complications, 
but only 35% of the patients with type 1 diabetes. This signiﬁ  cant difference is linked 
to insulin resistance and β-cell dysfunction, the underlying disorders in type 2 diabetes 
(Pickup and Williams 2002). Insulin resistance leads to increased β-cell activity, and 
the impairment of β-cell function is followed by a deterioration of the β-cell secretion 
product, leading to secretion of the insulin precursor proinsulin. While proinsulin has 
only about 10%–20% of the blood-glucose-lowering activity of insulin, it has comparable 
effects on the induction of adipogenesis (Pfützner et al 2006b). The consecutive growth 
of adipose tissue, however, is accompanied by a hormonal secretion pattern that impairs 
insulin resistance (Figure 1). With advancing disease progression, even more proinsulin 
is secreted, which is known to contribute to the increased cardiovascular risk by induc-
ing plasminogen activator inhibitor type-I (PAI-I) secretion, consecutively leading to an 
impairment of ﬁ  brinolysis (Schneider et al 1992; Pfützner et al 2004). 
Different treatment moieties are available to address these pathophysiological com-
ponents of type 2 diabetes. The ﬁ  rst attempt in primary care is usually to treat the patients 
with a combined approach of increased physical activity and dietary recommendations, 
which should be accompanied by patient training about the disease in order to increase 
the adherence to the required lifestyle changes. However in daily routine, lifestyle 
modiﬁ  cations are not consequently followed and a progressive deterioration of blood 
glucose metabolism leading to increased hemoglobin A1c (HbA1c) values requires 
the introduction of oral anti-diabetic agents. At this stage, several therapeutic options Vascular Health and Risk Management 2007:3(2) 212
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are available including metformin, sulfonylurea drugs (SU), 
thiazolidinediones, alpha-glucosidase inhibitors, and injectable 
or pulmonary insulin. While it would directly address β-cell 
dysfunction, insulin is not frequently used for therapy initiation 
because patients do not want to inject and the therapy is also not 
recommended as ﬁ  rst-line approach for economic reasons in 
many countries. The price of the drugs may also be the reason 
for the more hesitant use of thiazolidinediones (TZD) in initial 
diabetes mono-therapy. The currently most frequently pre-
scribed drugs for ﬁ  rst-line treatment are the SUs and metformin. 
In many therapeutic guidelines, metformin is recommended for 
obese patients while use of SUs is suggested in patients with 
normal or slightly increased body weight (American Diabetes 
Association 2006). 
With the currently predominantly used therapies, type 
2 diabetes appears to be a constantly progressing disease 
and mono-therapy may last for approximately 5–10 years 
before a further increase in HbA1c indicates the require-
ment of more intensive treatment regimens. At this stage, 
a second oral anti-diabetic drug will be introduced to 
increase the efﬁ  cacy of the therapeutic approach. One ap-
proach may be the combination of SU and TZD in order 
to beneﬁ  t from the synergistic therapeutic actions of both 
drug classes.
Rationale for the combination
Glimepiride [1-p-[[2-(3-ethyl-4-methyl-2-oxo-3-pyrro-
line-1-carboxamido) ethyl] phenyl] sulphonyl]-3-(trans-
4-methylcyclohexyl) urea] is a sulfonylurea drug that 
stimulates β-cell secretion by binding to a 65 kDa β-cell 
receptor leading to a decrease in gluco/hexokinase bind-
ing to porin proteins and an increase in the expression of 
glukokinase mRNA. The chemical structure is shown in 
Figure 2. The largest effects appear during the ﬁ  rst 4 hours 
after uptake and doses of 1–8 mg are usually given before 
or with breakfast. The extra-pancreatic effects seem to 
be similar to those of other SUs (McCall AL 2001). The 
unfavorable cardiovascular effects of SUs, eg, increase 
in diazoxide-induced KATP-channel opening, ST segment 
changes, and blood pressure increase, are less pronounced 
with glimepiride than with glibenclamide (Langtry and 
Balfour 1998). By increasing β-cell output, glimepiride 
lowers blood glucose levels and HbA1c, the major treat-
ment targets in the management of type 2 diabetes. Recent 
investigations describe an additional PPARγ-stimulating 
effect of glimepiride and an induction of endothelial NO 
synthesis, which makes glimepiride the most interesting SU 
candidate for a combination with TZDs (Fukuen et al 2005; 
Ueba et al 2005). 
A lifestyle change with regular performance of 
physical exercise and weight loss would be a normal 
and physiological way to improve insulin resistance, the 
second component of the underlying pathophysiology. 
The only drug class effectively addressing this condition 
is the class of thiazolidinediones or PPARγ-agonists, with 
two currently commercially available drugs, pioglitazone 
and rosiglitazone. The chemical structure of rosiglitazone 
[(±)-5-[[4-[2-(metyl-2-pyridinylamino) ethoxy] phenyl] 
methyl]-2, 4-thiazolidenedione, (Z)-2-butenedioate (1:1)] 
is also shown in Figure 2. TZDs activate the nuclear 
Figure 1 The relation of insulin resistance, β-cell dysfunction, obesity, and their associated complications.
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peroxisome proliferator-activated receptor (PPAR)γ, which 
is expressed predominately in adipose tissue and regulates 
the gene transcription involved in adipocyte differentiation 
and glucose and lipid metabolism (Kersten et al 2000; 
Schoonjans et al 2000; Debril et al 2001). The metabolic 
effects of PPARγ activation by rosiglitazone comprise an 
increase in peripheral insulin sensitivity in muscle, liver, 
and adipose tissue (Hallsten et al 2002; Wagstaff et al 
2002), improvement of postprandial and fasting glucose 
concentrations as well as long-term glucose control, 
improvement of adipogenesis leading to an increase in HDL 
cholesterol (Wagstaff et al 2002), reduction of vascular 
inﬂ  ammation (Natali et al 2004), improvement of arterial 
elasticity (Shargorodsky et al 2003), and a reduction of 
laboratory markers for cardiovascular risk (Haffner et al 
2002; Marx et al 2003a, b; Mohanty et al 2004; Pfützner 
et al 2006a).
The rationale for the ﬁ  xed combination is the synergistic 
effect of both substances via different modes of action on 
elevated blood glucose levels and the potential that the 
observed anti-inﬂ  ammatory effects of rosiglitazone at the 
vascular level may correct the expected negative inﬂ  uence 
of a SU on the chronic vascular inﬂ  ammation. 
Efﬁ  cacy and tolerability of the ﬁ  xed 
combination of glimepiride 
and rosiglitazone 
The ﬁ  xed combination of rosiglitazone has only recently 
been approved for clinical use. The idea of manufacturing 
a ﬁ  xed combination of rosiglitazone with a sulfonylurea 
drug came from the results of past clinical trials performed 
with the drugs given as separate tablets. An overview of 
the important published studies on this topic is provided 
in Table 1.
Studies comparing 
the rosiglitazone/SU combination 
vs SU mono-therapy
While the beneﬁ  t of adding rosiglitazone to sulfonylurea 
drugs was initially shown several years ago vs continuation 
of the pre-existing therapy in European, American, and Asian 
patients (Wolffenbüttel et al 2000; Vongthavaravat et al 2002; 
Yang et al 2003; Zhu et al 2003), a series of controlled clinical 
trials compared the addition of rosiglitazone to different sul-
fonylureas at a low dose (glibenclamide, gliclazide, glipizide, 
and glimepiride) with the uptitration of the respective SU 
drugs in patients at early disease stages (see below). 
Kerenyi et al (2004) compared the efﬁ  cacy of a daily com-
bination of 8 mg of rosiglitazone with 7.5 mg glibenclamide 
vs the uptitration of the SU, in a total of 340 patients with 
inadequately controlled type 2 diabetes (FPG ≥7.0 and ≤15.0 
mmol/L) on glibenclamide 7.5 mg/day. They were randomized 
to either additional treatment with rosiglitazone 8 mg/day or 
uptitration of the glibenclamide dose (maximum dose = 15 
mg/day) for an observation period of 26 weeks. Treatment with 
the rosiglitazone/SU combination reduced HbA1c by 0.91% 
and FPG by 2.4 mmol/L (intensiﬁ  ed glibenclamide mono-
therapy: HbA1c: –0.14%, FPG: +0.2 mmol/L, both p < 0.001 
compared with the combination). With the rosiglitazone/SU 
combination, an increase in HDL cholesterol by 15.8% and a 
decrease in free fatty acids by 15.3% and triglycerides by 5.8% 
could be observed. Both treatments were well tolerated and had 
predictable safety proﬁ  les, which led to the ﬁ  nal conclusion 
that addition of rosiglitazone provided signiﬁ  cantly improved 
glycemic control compared with uptitration of glibenclamide 
(Kerenyi et al 2004).
A second study investigated the TZD/SU combination 
with gliclazide as the SU component. A total of 471 patients 
with type 2 diabetes who were inadequately controlled on a 
Figure 2 Chemical structures of glimepiride and rosiglitazone. 
glimepiride rosiglitazone
O
N
O
O
N
S
N N
N N
N
O O
O O O
SVascular Health and Risk Management 2007:3(2) 214
Pfützner et al 
T
a
b
l
e
 
1
 
O
v
e
r
v
i
e
w
 
o
n
 
t
h
e
 
c
l
i
n
i
c
a
l
 
s
t
u
d
i
e
s
 
a
p
p
l
y
i
n
g
 
a
 
c
o
m
b
i
n
a
t
i
o
n
 
o
f
 
r
o
s
i
g
l
i
t
a
z
o
n
e
 
a
n
d
 
a
 
S
U
 
d
r
u
g
 
i
n
 
c
o
m
p
a
r
i
s
o
n
 
w
i
t
h
 
u
p
t
i
t
r
a
t
i
o
n
 
o
f
 
t
h
e
 
S
U
 
i
n
 
p
a
t
i
e
n
t
s
 
f
a
i
l
i
n
g
 
o
n
 
l
o
w
 
d
o
s
e
 
S
U
 
t
h
e
r
a
p
y
C
o
m
b
i
n
a
t
i
o
n
 
S
i
z
e
 
a
n
d
 
 
R
e
s
u
l
t
s
 
R
e
f
e
r
e
n
c
e
s
R
o
s
i
g
l
i
t
a
z
o
n
e
+
 
d
u
r
a
t
i
o
n
R
o
s
i
g
l
i
t
a
z
o
n
e
 
a
d
d
i
t
i
o
n
 
 
 
G
l
i
p
i
z
i
d
e
 
n
 
=
 
3
4
0
 
B
e
t
t
e
r
 
H
b
A
1
c
 
a
n
d
 
F
P
G
 
w
i
t
h
 
t
h
e
 
c
o
m
b
i
n
a
t
i
o
n
 
v
s
 
u
p
t
i
t
r
a
t
i
o
n
 
o
f
 
g
l
i
p
i
z
i
d
e
 
a
l
o
n
e
.
 
M
o
r
e
 
h
y
p
o
g
l
y
c
e
m
i
c
 
K
e
r
e
n
y
i
 
e
t
 
a
l
 
2
0
0
4
 
2
6
 
w
e
e
k
s
 
e
v
e
n
t
s
 
a
n
d
 
m
i
l
d
 
e
d
e
m
a
 
w
i
t
h
 
t
h
e
 
c
o
m
b
i
n
a
t
i
o
n
.
 
P
a
t
i
e
n
t
s
 
w
i
t
h
 
t
h
e
 
c
o
m
b
i
n
a
t
i
o
n
 
g
a
i
n
e
d
 
s
i
g
n
i
ﬁ
 
c
a
n
t
l
y
 
 
 
m
o
r
e
 
w
e
i
g
h
t
 
t
h
a
n
 
w
i
t
h
 
S
U
 
a
l
o
n
e
.
 
G
l
i
c
l
a
z
i
d
e
 
n
 
=
 
4
7
1
 
B
e
t
t
e
r
 
H
b
A
1
c
 
a
n
d
 
F
P
G
 
w
i
t
h
 
t
h
e
 
c
o
m
b
i
n
a
t
i
o
n
 
v
s
 
u
p
t
i
t
r
a
t
i
o
n
 
o
f
 
g
l
i
c
l
a
z
i
d
e
 
a
l
o
n
e
.
 
M
o
r
e
 
h
y
p
o
g
l
y
c
e
m
i
c
 
B
a
k
s
i
 
e
t
 
a
l
 
2
0
0
4
 
2
6
 
w
e
e
k
s
 
e
v
e
n
t
s
 
a
n
d
 
o
e
d
e
m
a
 
w
i
t
h
 
t
h
e
 
c
o
m
b
i
n
a
t
i
o
n
.
 
P
a
t
i
e
n
t
s
 
w
i
t
h
 
t
h
e
 
c
o
m
b
i
n
a
t
i
o
n
 
g
a
i
n
e
d
 
s
i
g
n
i
ﬁ
 
c
a
n
t
l
y
 
m
o
r
e
 
 
 
 
w
e
i
g
h
t
 
t
h
a
n
 
w
i
t
h
 
S
U
 
a
l
o
n
e
.
 
G
l
i
b
e
n
c
l
a
m
i
d
e
 
n
 
=
 
2
2
7
 
B
e
t
t
e
r
 
H
b
A
1
c
 
a
n
d
 
F
P
G
 
w
i
t
h
 
t
h
e
 
c
o
m
b
i
n
a
t
i
o
n
 
v
s
 
u
p
t
i
t
r
a
t
i
o
n
 
o
f
 
g
l
i
b
e
n
c
l
a
m
i
d
e
 
a
l
o
n
e
.
 
 
R
o
s
e
n
s
t
o
c
k
 
e
t
 
a
l
 
2
0
0
5
 
 
2
 
y
e
a
r
s
 
C
o
m
p
a
r
a
b
l
e
 
i
n
c
i
d
e
n
c
e
 
o
f
 
h
y
p
o
g
l
y
c
a
e
m
i
c
 
e
v
e
n
t
s
.
 
M
o
r
e
 
m
i
l
d
 
o
e
d
e
m
a
 
w
i
t
h
 
t
h
e
 
c
o
m
b
i
n
a
t
i
o
n
.
 
 
 
H
e
r
m
a
n
 
e
t
 
a
l
 
2
0
0
5
 
 
 
 
 
P
a
t
i
e
n
t
s
 
w
i
t
h
 
t
h
e
 
c
o
m
b
i
n
a
t
i
o
n
 
g
a
i
n
e
d
 
s
i
g
n
i
ﬁ
 
c
a
n
t
l
y
 
m
o
r
e
 
w
e
i
g
h
t
 
t
h
a
n
 
w
i
t
h
 
S
U
 
a
l
o
n
e
.
 
G
l
i
m
e
p
i
r
i
d
e
 
n
 
=
 
3
9
1
 
B
e
t
t
e
r
 
H
b
A
1
c
 
a
n
d
 
F
P
G
 
w
i
t
h
 
t
h
e
 
c
o
m
b
i
n
a
t
i
o
n
 
v
s
 
u
p
t
i
t
r
a
t
i
o
n
 
o
f
 
g
l
i
m
e
p
i
r
i
d
e
 
a
l
o
n
e
.
 
R
o
s
e
n
s
t
o
c
k
 
e
t
 
a
l
 
2
0
0
5
 
3
0
 
w
e
e
k
s
 
M
o
r
e
 
h
y
p
o
g
l
y
c
a
e
m
i
c
 
e
v
e
n
t
s
 
a
n
d
 
m
i
l
d
 
o
e
d
e
m
a
 
w
i
t
h
 
t
h
e
 
c
o
m
b
i
n
a
t
i
o
n
.
 
P
a
t
i
e
n
t
s
 
w
i
t
h
 
t
h
e
 
 
 
 
c
o
m
b
i
n
a
t
i
o
n
 
g
a
i
n
e
d
 
s
i
g
n
i
ﬁ
 
c
a
n
t
l
y
 
m
o
r
e
 
w
e
i
g
h
t
 
t
h
a
n
 
w
i
t
h
 
S
U
 
a
l
o
n
e
.
G
l
i
m
e
p
i
r
i
d
e
 
n
 
=
 
1
7
4
 
 
B
e
t
t
e
r
 
H
b
A
1
c
 
a
n
d
 
F
P
G
 
w
i
t
h
 
t
h
e
 
c
o
m
b
i
n
a
t
i
o
n
 
(
w
i
t
h
 
u
p
t
i
t
r
a
t
i
o
n
 
o
f
 
r
o
s
i
g
l
i
t
a
z
o
n
e
)
 
v
s
 
g
l
i
m
e
p
i
r
i
d
e
 
H
a
m
a
n
n
 
e
t
 
a
l
 
2
0
0
3
 
2
6
 
w
e
e
k
s
 
a
l
o
n
e
.
 
I
m
p
r
o
v
e
m
e
n
t
 
o
f
 
i
n
ﬂ
 
a
m
m
a
t
o
r
y
 
r
i
s
k
 
m
a
r
k
e
r
s
,
 
i
n
s
u
l
i
n
 
r
e
s
i
s
t
a
n
c
e
 
a
n
d
 
β
-
c
e
l
l
 
f
u
n
c
t
i
o
n
 
i
n
 
t
h
e
 
P
f
ü
t
z
n
e
r
 
e
t
 
a
l
 
2
0
0
6
a
 
 
r
o
s
i
g
l
i
t
a
z
o
n
e
 
a
r
m
s
 
o
n
l
y
.
 
C
o
m
p
a
r
a
b
l
e
 
i
n
c
i
d
e
n
c
e
 
o
f
 
h
y
p
o
g
l
y
c
e
m
i
c
 
e
v
e
n
t
s
.
 
M
o
r
e
 
m
i
l
d
 
e
d
e
m
a
 
w
i
t
h
 
 
 
t
h
e
 
c
o
m
b
i
n
a
t
i
o
n
.
 
P
a
t
i
e
n
t
s
 
w
i
t
h
 
t
h
e
 
8
 
m
g
 
c
o
m
b
i
n
a
t
i
o
n
 
g
a
i
n
e
d
 
s
i
g
n
i
ﬁ
 
c
a
n
t
l
y
 
m
o
r
e
 
w
e
i
g
h
t
 
t
h
a
n
 
 
w
i
t
h
 
S
U
 
a
l
o
n
e
.
 
G
l
i
m
e
p
i
r
i
d
e
 
a
d
d
i
t
i
o
n
 
 
 
G
l
i
m
e
p
i
r
i
d
e
 
n
 
=
 
4
0
 
B
e
t
t
e
r
 
H
b
A
1
c
 
a
n
d
 
F
P
G
 
w
i
t
h
 
t
h
e
 
c
o
m
b
i
n
a
t
i
o
n
 
i
n
 
p
a
t
i
e
n
t
s
 
f
a
i
l
i
n
g
 
o
n
 
r
o
s
i
g
l
i
t
a
z
o
n
e
 
m
o
n
o
t
h
e
r
a
p
y
.
 
M
c
C
l
u
s
k
e
y
 
e
t
 
a
l
 
2
0
0
4
 
2
6
 
w
e
e
k
s
 
N
o
 
i
n
c
r
e
a
s
e
 
i
n
 
h
y
p
o
g
l
y
c
e
m
i
c
 
e
p
i
s
o
d
e
s
 
o
r
 
o
t
h
e
r
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
.
 
 
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
F
P
G
,
 
f
a
s
t
i
n
g
 
p
l
a
s
m
a
 
g
l
u
c
o
s
e
;
 
H
b
A
1
c
,
 
h
e
m
o
g
l
o
b
i
n
 
A
1
c
;
 
S
U
,
 
s
u
l
f
o
n
y
l
u
r
e
a
.Vascular Health and Risk Management 2007:3(2) 215
Rosiglitazone and glimeperide ﬁ  xed dose combination
half-maximal dose of gliclazide (160 mg/day) were random-
ized to receive either the addition of rosiglitazone (4 mg bid) 
or to have their gliclazide uptitrated to a maximum of 320 
mg/day during a 26-week treatment period. A reduction in 
HbA(1c) of 1.3% (p < 0.001) was observed in the combina-
tion treatment group compared with the uptitrated gliclazide 
at endpoint. The proportion of patients who achieved an 
HbA1c value <7% was also greater in the combination group 
(48% vs 22%). FPG was reduced by 3.0 mmol/L (p < 0.001) 
in the rosiglitazone/SU group compared with the uptitrated 
gliclazide group after 26 weeks. The observed side-effects 
included an increased incidence of signs or symptoms sug-
gestive of hypoglycemia with rosiglitazone/SU compared 
with uptitrating the gliclazide dose (6% vs 2%). Only 1% 
of patients reported severe hypoglycemia. The combination 
treatment led to increases in plasma lipoproteins, and more 
patients experienced edema (11% vs 3%). A signiﬁ  cant 
increase in body weight was observed in patients receiv-
ing rosiglitazone plus gliclazide vs uptitrated gliclazide 
(3.4 kg; p < 0.001). The authors concluded that the addition 
of rosiglitazone (4 mg bid) to gliclazide (160 mg/day) was 
well tolerated, and signiﬁ  cantly more effective in improving 
glycemia than uptitrating gliclazide to 320 mg/day (Baksi 
et al 2004).
The aim of a recently published study (Rosenstock et al 
2005) in older patients with type 2 diabetes was to compare 
the efﬁ  cacy, safety, and tolerability of adding rosiglitazone 
vs glipizide dose escalation when the patients were inad-
equately controlled on low dose SU therapy. A total of 
227 patients (age: >60 years) were randomized to receive 
rosiglitazone (4 mg) or placebo once daily in combination 
with glipizide 10 mg twice daily for 2 years in a doub-
le-blind, parallel-group study design. Treatment options 
were individualized, and escalation of study medication 
was speciﬁ  cally deﬁ  ned. Disease progression, deﬁ  ned as 
the time to reach conﬁ  rmed FPG >10 mmol/L while on 
maximum doses of both glipizide and study medication 
or placebo, was reported in 28.7% of patients uptitrating 
glipizide plus placebo compared with only 2.0% taking 
rosiglitazone and glipizide combination (p < 0.001). The 
combination signiﬁ  cantly decreased HbA1c, FPG, insulin 
resistance, and plasma free fatty acids. The authors con-
cluded that the addition of rosiglitazone to SU in older 
patients with type 2 diabetes signiﬁ  cantly improved gly-
cemic control and reduced disease progression compared 
with uptitrated glipizide alone and without increasing 
hypoglycemia. These beneﬁ  ts were associated with in-
creased patient treatment satisfaction and reduced medi-
cal care utilization in terms of emergency room visits and 
length of hospitalization (Herman et al 2005; Rosenstock 
et al 2005).
The purpose of a fourth clinical trial (Rosenstock et al 
2006b), a 24-week, randomized, double-blind, controlled 
study, was to demonstrate that the early addition of ros-
iglitazone to submaximal therapeutic doses of glimepiride 
leads to greater glycemic improvement than uptitration of 
glimepiride to maximal dose. Prior to study entry, subjects 
were treated with a single oral agent or low-dose oral combi-
nation therapy. Mean duration of diabetes was approximately 
5 years in the two treatment groups. All subjects received 
low-dose glimepiride (2 mg) during a 6-week run-in period. 
At randomization, subjects either added 4 mg of rosiglitazone 
to the glimepiride dose (add-on group) or added placebo 
to an increased glimepiride dose (4 mg, uptitration group) 
once daily. After 8 weeks, glimepiride was increased to 4 
mg in the rosiglitazone add-on group (n = 180) or to 8 mg in 
the glimepiride uptitration group (n = 181), if fasting blood 
glucose was ≥110 mg/dL. While no change from baseline 
in HbA1c or FPG was observed in the uptitration group 
(–0.08%; –0.6 mg/dL, not signiﬁ  cant in both cases), a sig-
niﬁ  cant reduction in both observation parameters was seen 
in the rosiglitazone add-on group (–0.68%; –27.7 mg/dL; 
p < 0.05 in both cases and between groups). In this study, 
the addition of rosiglitazone to low-dose glimepiride led to 
clinically and statistically signiﬁ  cant decreases in HbA1c and 
FPG levels compared with uptitration of glimepiride alone, 
and more subjects reached the ADA goal of HbA1c <7% 
(63.9% vs 39.8%, p < 0.05). Addition of rosiglitazone also 
showed signiﬁ  cant improvements in HOMA β-cell function 
(18%) and insulin sensitivity (15%) estimates relative to 
glimepiride alone (p < 0.05). Both therapies were well toler-
ated. The incidence of hypoglycemia with blood glucose ≤50 
mg/dL was low and similar between the groups. The authors 
concluded that their study supported the paradigm that early 
introduction of oral combination therapy is more effective 
in achieving glycemic control than increasing doses of SU 
mono-therapy, without increasing the risk of conﬁ  rmed 
hypoglycemia (Rosenstock et al 2006b).
In another randomized double-blind parallel study with 
patients with type 2 diabetes, 3 mg of glimepiride was used as 
a baseline therapy in all treatment groups. Based on the ran-
domization scheme, the patients received additional treatment 
with placebo (group 0), 4 mg (group 4), or 8 mg (group 8) of 
rosiglitazone for 4 months. The investigation was performed 
to assess efﬁ  cacy and safety of the rosiglitazone/glimepiride 
combination therapy (HbA1c, FPG, hypoglycemia, and Vascular Health and Risk Management 2007:3(2) 216
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adverse events). The combination of 4 mg or 8 mg of rosi-
glitazone with glimepiride 3 mg signiﬁ  cantly improved 
glycemic control compared with glimepiride alone. HbA1c 
levels were signiﬁ  cantly reduced from baseline in group 
4 by –0.63% and group 8 by –1.17%, but not in group 0 
(–0.08%, p < 0.001 vs both other groups). FPG was sig-
niﬁ  cantly reduced in group 8 vs group 0 (p < 0.001) and a 
greater proportion of patients treated with the combination 
achieved target levels of HbA1c (ADA goal of HbA1c <7%: 
group 4: 43%; group 8: 68% vs group 0: 32%). Mean body 
weight increased in group 8 by 1.7 kg (p < 0.01 vs baseline), 
whereas the weight gain with the lower rosiglitazone dose 
was not signiﬁ  cantly different from that with the glimepir-
ide mono-therapy arm. All treatments were generally well 
tolerated with no signiﬁ  cant differences in the incidence or 
proﬁ  le of adverse events between the treatment groups. There 
were no withdrawals due to hypoglycemia, hepatotoxicity, or 
edema. In particular, combination treatment did not increase 
the incidence of hypoglycemia compared with glimepride 
alone (Hamman et al 2003).
For a subgroup of 102 patients (group 0: n = 30; group 
4: n = 31; group 8: n = 41; 46 women, 56 men, mean age: 
62.8 ± 9.1 years, BMI 28.7 ± 4.5 kg/m2, diabetes duration 
6.4 ± 4.8 years, HbA1c 8.1 ± 1.5%), additional samples were 
available from this study for assessment of HOMAIR score, 
insulin, intact proinsulin, and adiponectin after 0 and 16 
week of treatment. Insulin resistance was deﬁ  ned by elevated 
intact proinsulin values or HOMAIR >2. All parameters were 
comparable in the three groups at baseline. While no changes 
were seen for any of the observation parameters except an in-
crease in adiponectin from 8.4 ± 5.1 mg/L to 11.9 ± 6.2 mg/L 
(+42%, p < 0.001) with glimepiride alone, substantial and sig-
niﬁ  cant dose-dependent improvements were observed after 
addition of rosiglitazone for fasting glucose (group 0: –9 ± 48 
mg/dL; group 4: –38 ± 47 mg/dL; group 8: –46 ± 53 mg/dL), 
HbA1c (–0.1 ± 0.7%; −1.1 ± 1.2%; –1.3 ± 1.2%), insulin 
(+1.4 ± 6.2 µU/mL; –1.2 ± 5.3 µU/mL; –3.7 ± 9.9 µU/mL), 
and intact proinsulin (+1.6 ± 7.1 pmol/L; –2.0 ± 4.6 pmol/L; 
–3.1 ± 6.1 pmol/L). After adjustment for changes in body 
weight, a signiﬁ  cant additional contribution of PPARγ acti-
vation (p < 0.001) to the adiponectin increase was detected, 
while glimepiride alone did not induce a comparable effect 
(–0.5 ± 5.8 mg/L; +8.8 ± 22.9 mg/L; +14.3 ± 19.9 mg/L). 
The number of insulin-resistant patients decreased in both 
rosiglitazone treatment groups, while no change was seen 
with glimepiride alone. Next to the reported effects on glu-
cose control, rosiglitazone provided an additional beneﬁ  cial 
effect on insulin resistance and β-cell function leading to 
lower HOMAIR scores, lower values for insulin, and intact 
proinsulin, and a more pronounced increase in adiponectin 
values. These results supported the clinical rationale of 
combining rosiglitazone with sulfonylurea drugs in patients 
with type 2 diabetes (Pfützner et al 2006a).
In accordance with the current treatment guidelines, 
rosiglitazone was added to a SU drug in all aforementioned 
trials, but McCluskey et al (2004) investigated the converse 
situation. A total of 40 patients who failed on rosiglitazone 
mono-therapy were treated with additional glimepiride vs 
placebo for 26 weeks. The outcomes were greater reductions 
for the glimepiride vs the placebo combination in HbA1c 
(mean [SE], –12% [0.1%] vs –3% [2%]; p < 0.001) and 
FPG (mean [SE], –24.4 [6.0] mg/dL vs 5.9 [8.0] mg/dL; 
p < 0.01). More patients in the glimepiride group achieved 
the HbA1c target of ≤7% (60% vs 14%; p < 0.01). There 
were no signiﬁ  cant differences in the rate or type of adverse 
events between groups, and no episodes of severe 
hypoglycemia occurred with either treatment (McCluskey 
et al 2004). It needs to be pointed out, however, that the 
inclusion criteria of the patients in this trial may have 
potentially resulted in selection of pharmacological non-
responders to rosiglitazone therapy, but unfortunately no 
pharmacogenetic characterization is provided for the trial 
participants in this manuscript. 
Addition of pioglitazone (15 mg) or rosiglitazone (4 mg) 
to glimepiride in patients with type 2 diabetes and metabolic 
syndrome for 12 months in a double-blind randomized par-
allel trial resulted in a comparable reduction in HbA1c and 
FPG with both drugs, comparable improvement of insulin 
resistance and the prothrombotic state, but with better lipid 
values resulting from the pioglitazone/glimepiride combina-
tion. In general, however, the overall efﬁ  cacy and side-effect 
proﬁ  les of both TZD/SU combinations were considered to be 
beneﬁ  cial for the metabolic control of the patients (Derosa 
et al 2004 and 2005a). 
In summary, all these dual combination trials have dem-
onstrated that the use of rosiglitazone together with sulfo-
nylurea drugs provides a better glycemic control compared 
with further intensifying the SU mono-therapy. This result 
was accompanied by an improvement in the cardiovascular 
risk proﬁ  le of the patients. The metabolic improvements were 
associated with an equal or increased number of hypoglyce-
mic events. However, this increase in hypoglycemia needs 
to be analyzed in the context of the observed parallel HbA1c 
improvements. Other observed side-effects of the TZD/SU 
combination vs SU alone were increases in body weight and 
an increased incidence of mild edema, which are established Vascular Health and Risk Management 2007:3(2) 217
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side-effects of rosiglitazone therapy. The combination was 
well tolerated and no indications of hepatotoxicity were 
observed in any of the trials. 
Studies of rosiglitazone/SU in other 
treatment combinations 
In the past, the usual oral combination to be prescribed after 
failure of SU or metformin mono-therapy was the combination 
of SU with metformin. Some studies have investigated the 
combination of rosiglitazone with metformin vs metformin/SU 
(eg, Derosa et al 2005b, 2006), but no investigation is available 
comparing rosiglitazone/glimepiride with the metformin/SU 
combination. In comparison with metformin, rosiglitazone 
decreases liver fat and increases peripheral glucose uptake. 
The decrease in liver fat is associated with an increase in 
serum adiponectin concentrations (Tiikainen et al 2004). 
Rosiglitazone positively affects CV risk markers, reducing 
plasmatic concentration of C-reactive protein (PCR-), matrix 
metallo-proteinases (MMP-9), tumor necrosis factor-alpha 
(TNF-alpha), serum amyloid, and soluble CD40L in type 2 dia-
betic patients with and without coronary disease (Wellington 
2005). These effects seem to be conserved when rosiglitazone 
is used in combination with glimepiride (Pfützner et al 2006a) 
and both drugs are, therefore, interesting candidates also for 
multiple component therapies, especially when a ﬁ  xed-dose 
combination of rosiglitazone and glimepiride may help to 
reduce the number of daily tablets. 
Orbay et al (2004) investigated the addition of rosi-
glitazone to a combination of glimepiride and metformin 
therapy in patients with insufﬁ  ciently controlled type 2 dia-
betes over 26 weeks. Thirty patients were taking glimepiride 
(3 mg) and metformin (850 mg) two times per day and 
added rosiglitazone (4 mg) before breakfast. Mean HbA1c 
levels decreased signiﬁ  cantly from 7.54 ± 0.9% to 6.57 
± 0.7% (p < 0.001) and FPG levels fell from 169 ± 38 mg/dL 
to 136 ± 28 mg/dL (p < 0.001), respectively. Insulin levels 
decreased from 19.6 ± 9.8 U/L to 14.7 ± 11.6 U/L (p < 0.05) 
at endpoint. No elevations of alanine aminotransferase or 
aspartate aminotransferase levels greater than 2.5 times the 
upper limit of the reference range were observed. This study 
conﬁ  rmed that the addition of rosiglitazone (4 mg/day) to SU 
and metformin treatment may provide a promising approach 
to achieve target levels of glycemia (Orbay et al 2004).
A different study by Roberts et al (2005) evaluated the 
efﬁ  cacy and tolerability of glimepiride in patients with type 
2 diabetes mellitus that were inadequately controlled with a 
combination of immediate- or extended-release metformin 
and a thiazolidinedione. In this multicenter, randomized, 
double-blind, placebo-controlled, parallel-group, 2-arm 
study consisting of a 4-week stabilization and eligibility 
period and a 26-week treatment period, 170 patients with 
type 2 diabetes received glimepiride (uptitration possible) 
or placebo in combination with an established regimen 
of immediate- or extended-release metformin and rosi-
glitazone or pioglitazone. Demographic variables were 
similar at baseline between the glimepiride and placebo 
groups. HbA1c was signiﬁ  cantly improved at endpoint with 
glimepiride combination therapy compared with placebo 
(mean [SE], –1.31% [0.08] vs –0.33% [0.08], respectively; 
p < 0.001). Most patients (62.2%) who received glimepiride 
achieved an HbA1c value of ≤7%, compared with 26.0% of 
patients receiving placebo (p < 0.001 between groups). Pa-
tients on glimepiride therapy had a higher BMI at endpoint 
(adjusted change from baseline to endpoint 1.26 ± 0.16 
kg/m2 with glimepiride and 0.17 ± 0.16 kg/m2 with placebo 
(p < 0.001). There were no signiﬁ  cant differences in lipid 
levels between groups. Clinically signiﬁ  cant adverse events, 
laboratory abnormalities, and rates of severe hypoglycemia 
were similar between treatment groups. The overall incidence 
of hypoglycemia, however, was 51.2% in the glimepiride 
group and 8.3% in the placebo group (p < 0.001). This 
study showed that in these patients with type 2 diabetes not 
adequately controlled by dual combination therapy with met-
formin and a thiazolidinedione, the addition of glimepiride 
improved glycemic control compared with placebo with an 
acceptable tolerability proﬁ  le. Although there were signiﬁ  -
cantly more episodes of hypoglycemia with triple therapy 
than with dual therapy and placebo, the risk for severe hy-
poglycemia was low. This study again supports the use of 
glimepiride in conjunction with TZD combination therapies 
(Roberts et al 2005). 
A controlled study investigating the effects of adding 
rosiglitazone in comparison to a long acting insulin analogue 
on metabolic control in patients inadequately controlled with 
a metformin/SU combination therapy was recently published 
by Rosenstock et al (2006b). In this 24-week multicenter, 
randomized, open-label, parallel trial, 217 patients (HbA1c: 
7.5%–11%, BMI >25 kg/m²) on ≥50% of maximal-dose 
SU and metformin received add-on insulin glargine 10 
units/day or rosiglitazone 4 mg/day. Insulin glargine was 
forced-titrated to target FPG (≤100–120 mg/dL), and rosi-
glitazone was increased to 8 mg/day any time after 6 weeks, 
if FPG was >5.5 mmol/L. A similar improvement in HbA1c 
was observed in both groups (–1.7% vs –1.5% for insulin 
glargine vs rosiglitazone, respectively). When baseline 
HbA1c was >9.5%, the reduction with insulin glargine was Vascular Health and Risk Management 2007:3(2) 218
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greater than with rosiglitazone (p < 0.05). Also, insulin 
glargine yielded better FPG values than rosiglitazone (–3.6 
± 0.23 mmol/L vs –2.6 ± 0.22 mmol/l; p < 0.001). The ﬁ  nal 
daily insulin glargine dose was 38 ± 26 IU vs 7.1 ± 2 mg for 
rosiglitazone. Conﬁ  rmed hypoglycemic events at plasma 
glucose <3.9 mmol/L (<70 mg/dL) were slightly greater for 
the insulin glargine group (n = 57) than for the rosiglitazone 
group (n = 47) (p = 0.0528). More patients in the insulin 
glargine group had conﬁ  rmed nocturnal hypoglycemia of <3.9 
mmol/L (p < 0.05) and <2.8 mmol/L (p < 0.05) than in the 
rosiglitazone group. The effects on total and LDL cholesterol, 
and triglyceride levels with insulin glargine contrasted with 
those of rosiglitazone (–4.4%, –1.4%, and –19.0% vs +10.1%, 
+13.1%, and +4.6%, respectively; p < 0.005). HDL choles-
terol was unchanged with insulin glargine but increased with 
rosiglitazone by 4.4%, p < 0.05). Insulin glargine led to less 
weight gain than rosiglitazone (1.6 ± 0.4 kg vs 3.0 ± 0.4 kg; 
p < 0.05), fewer adverse events (7% vs 29%; p < 0.001), and 
no peripheral edema (0 vs 12.5%). In conclusion, both triple 
therapies achieved comparable improvements in HbA1c. 
Rosiglitazone was associated with less hypoglycemia and 
more weight gain (Rosenstock et al 2006a).
As shown above, many studies suggest the use of a rosi-
glitazone/SU combination in different stages of type 2 dia-
betes. Further studies supporting the concept and efﬁ  cacy of 
the ﬁ  xed dose combination of rosiglitazone with glimepiride 
are currently under way and their results will soon become 
publicly available. 
Recent ﬁ  ndings from the ADOPT trial, a monotherapy 
outcome study comparing rosiglitazone, metformin, and 
glyburide over four years (Kahn et al 2006), showed the typi-
cal side-effects of each drug class. Gastrointestinal problems 
were most frequently observed with metformin, sulfonylureas 
led to hypoglycaemia, and weight gain and edema were most 
frequently seen with rosiglitazone. In addition, there was a 
small but signiﬁ  cant number of leg and forearm fractures in 
postmenopausal women with rosiglitazone. As it is known 
that PPARγ activation may inﬂ  uence bone metabolism, further 
research is required to elucidate the impact of these ﬁ  ndings 
on the risk/beneﬁ  t analysis of the rosiglitazone/glimepiride 
combination. 
Quality of life and patient 
satisfaction
The ﬁ  xed combination of glimepiride with rosiglitazone 
has only been recently approved. Therefore, no report 
focussing on patient satisfaction with this ﬁ  xed combina-
tion has been published yet. Improved patient satisfaction 
with the combination of rosiglitazone and glipizide given 
as separate tablets was already reported from the RESULT 
study (Rosenstock et al 2005; Herman et al 2005). It can, 
therefore, be expected that the additional reduction of the 
daily number of tablets to be taken may lead to an even 
better treatment satisfaction and adherence of the patients 
to their therapy. 
Conclusion 
The combination of rosiglitazone with glimepiride has been 
investigated in multiple trials, some of which especially 
addressed the beneﬁ  t of adding a TZD in early stages to 
low-dose SU therapy vs increasing the SU dose or a head-
to-head comparison with the SU/metformin combination. 
Introducing the synergistic effects of both drug classes at 
these stages improved overall glycemic control without 
necessarily increasing the risk for hypoglycemic episodes, 
and with a safety proﬁ  le comparable with rosiglitazone 
mono-therapy. In all studies, more patients on the combi-
nation therapy reached the HbA1c treatment target com-
pared with the respective comparator arms. While these 
trials provide the scientiﬁ  c rationale for combining TZDs 
with SUs, the introduction of a ﬁ  xed-dose combination of 
rosiglitazone and glimepiride may be regarded as a helpful 
tool to increase patients convenience, since it reduces the 
number of daily tablets. It may, therefore, support patients’ 
adherence to the essential anti-diabetic therapy. The avail-
able pharmacological formulations, allowing for up- or 
downtitration of the glimepiride doses, may be welcomed 
by physicians as a means of responding to a potentially 
increased number of hypoglycemic events without losing 
metabolic efﬁ  cacy.
Place in therapy  
Based on published investigations, the place for the ﬁ  xed-
dose combination of rosiglitazone and glimepiride may be 
as a second-line therapeutic approach in patients failing on 
low- to mid-dose SU mono-therapy and in the triple combi-
nation with metformin. In this treatment segment, this ﬁ  xed 
combination has to compete with the ﬁ  xed combination of 
pioglitazone with glimepriride, which has also been approved 
recently in the US and Europe.
As mentioned above, the ﬁ  xed combination of rosi-
glitazone with glimepiride is available as single tablet 
formulation containing 4 mg of rosiglitazone with either 
1 mg, 2 mg, or 4 mg of glimepiride. It should be given once 
daily with the ﬁ  rst meal of the day and dosage should be Vascular Health and Risk Management 2007:3(2) 219
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adapted to individual needs in order to obtain the optimal 
glycemic control with the lowest incidence of adverse 
events, particularly severe hypoglycemia and heart failure. 
The maximum recommended dose is 8 mg of rosiglitazone 
and 4 mg of glimepiride. The recommended starting dose 
for patients inadequately controlled with SU alone or who 
had initially responded to rosiglitazone and require a better 
glycemic control, is 4 mg/1 mg. This starting dose is also 
recommended in elderly and debilitated patients and in case 
of renal, hepatic, or adrenal insufﬁ  ciency. When switching 
from a combination therapy of rosiglitazone plus glimepiride 
as separate tablets, the corresponding ﬁ  xed-dose formulation 
should be taken and sufﬁ  cient time should be given to assess 
adequacy of therapeutic response. If hypoglycemia occurs 
during the titration, the dose of glimepiride may be reduced 
(GlaxoSmithKline 2006). 
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